SINOPHARM GROUP 1/5/O.N. Financial Flexibility Index
SINOPHARM GROUP 1/5/O.N. financial flexibility index. SINOPHARM GROUP 1/5/O.N. (X2S1) has a Financial Flexibility Index of 0.06x as of December 2025. Free cash flow of €15.76 Billion (operating CF €14.14 Billion minus capex €1.62 Billion) represents 0% of total liabilities (€256.20 Billion). See SINOPHARM GROUP 1/5/O.N. (X2S1) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of SINOPHARM GROUP 1/5/O.N. (2021–2025)
Financial flexibility index of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025. Historical Financial Flexibility Index trend for SINOPHARM GROUP 1/5/O.N. across 5 annual periods. Check X2S1 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
SINOPHARM GROUP 1/5/O.N. Financial Flexibility Index by Year (2021–2025)
SINOPHARM GROUP 1/5/O.N. financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for SINOPHARM GROUP 1/5/O.N.. For the full cash flow conversion analysis, see cash efficiency ratio of SINOPHARM GROUP 1/5/O.N..
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.06x | €15.76 Billion | €14.14 Billion | €256.20 Billion | ▲ +21.1% |
| 2024 | 0.05x | €13.51 Billion | €11.55 Billion | €266.14 Billion | ▼ -31.5% |
| 2023 | 0.07x | €19.51 Billion | €17.17 Billion | €263.08 Billion | ▼ -19.2% |
| 2022 | 0.09x | €23.38 Billion | €20.96 Billion | €254.71 Billion | ▲ +87.2% |
| 2021 | 0.05x | €11.56 Billion | €9.31 Billion | €235.76 Billion | — |